|Jul 27, 2005
|ELITE PHARMACEUTICALS TO PRESENT AT THE BANC OF AMERICA SECURITIES 2005 SPECIALTY PHARMACEUTICS CONFERENCE
|Presentation Schedule Change
Northvale, New Jersey, Wednesday, July 27, 2005: Elite Pharmaceuticals, Inc. (AMEX: ELI) is pleased to announce that the Company has been invited to present at Banc of America Securities 2005 Specialty Pharmaceuticals Conference scheduled for Wednesday, July 27 through Friday, July 29, 2005, at the Southampton Inn in Southampton, New York. The theme of this year’s conference is “New Products, New Paradigms". Bernard Berk, Chairman & CEO, will give Elite’s presentation on Thursday, July 28th at 3:00 PM. Also representing the Company will be Charan Behl, Ph.D., Elite’s Chief Scientific Officer and Chris Dick, Senior Vice President of Business Development.
A replay of the presentation will be available on the Company’s website at http://www.elitepharma.com approximately 3 hours after the event and will be available through August 12, 2005.
About Elite Pharmaceuticals
Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development of oral, controlled release products. The Company's strategy includes developing generic versions of controlled release drug products with high barriers to entry and assisting partner companies in the life cycle management of products to improve off-patent drug products. Elite's technology is applicable to develop delayed, sustained or targeted release capsules or tablets. Elite has one product currently being sold commercially and a pipeline of six drug products under development in the therapeutic areas that include pain management, allergy, cardiovascular and infection. The addressable market for Elite's current pipeline of products exceeds $6 billion. Elite also has a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
FOR FURTHER INFORMATION, CONTACT:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
Phone: 518-398-6222 E-Mail: email@example.com
This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite or Pliva, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in the Elite’s filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. The companies undertake no obligation to update any forward-looking statements.